March 28, 2024

NeuroOne Initiates Commercial Launch of OneRF™ Ablation System

NeuroOne Medical Technologies (Nasdaq: NMTC) has initiated a limited commercial launch of its OneRF™ Ablation System, a stereoelectroencephalogram (sEEG)-guided tool used in neurosurgery to record electrical activity and ablate nervous tissue under temperature-controlled environments. It is NeuroOne’s first device with a therapeutic indication, and the company’s third FDA 510(k)-cleared device. NeuroOne is targeting a significant… [Read More]
March 28, 2024

PRISM Stocks to Watch: Puff Puff Pass-ing Legislation for Canadian Cannabis Tax Reform Talks

As cannabis becomes formally recognized as a non-narcotic in Germany next week, other countries have been considering some legislative initiatives that may positively impact the industry and related stocks. The Canadian government has been considering revising its excise tax framework. This revision would lessen the tax burden for cannabis companies with Canadian exposure . As… [Read More]
March 27, 2024

PAVmed Shares Climb Following Earnings Surpass

PAVmed Inc. (NASDAQ: PAVM), a diversified medical device company, experienced a notable surge in its stock price after outperforming earnings expectations. Highlights: PAVmed’s Q4 Non-GAAP EPS of -$1.33 surpassed estimates by $0.47, with revenue climbing to $1.05 million, indicating a substantial year-over-year increase. Year-end cash and equivalents stood at $19.6 million, down from $39.7 million,… [Read More]
March 27, 2024

Reddit Expands Revenue Streams with New Data-Licensing Agreement with Cision

Reddit ( $RDDT) Announces New Data-Licensing Agreement Reddit has announced a new data-licensing agreement with Cision, a public-relations software company. This announcement comes after the company’s recent initial public offering and its first such agreement with Google. Reddit, which started charging for data access last year after previously offering it for free, has identified Cision… [Read More]
March 27, 2024

iBio and AstralBio Forge AI Drug Discovery Alliance to Target Obesity and Cardiometabolic Diseases; Shares Skyrocket 226%

iBio, Inc. (NYSEA:IBIO), in partnership with AstralBio, Inc., has launched a collaboration to leverage artificial intelligence (AI) in the discovery and development of novel antibodies aimed at treating obesity and cardiometabolic diseases. This partnership combines iBio’s AI and machine learning capabilities alongside AstralBio’s experience in biologics and drug development to create treatments targeting specific health… [Read More]
March 27, 2024

PRISM Market Moves on Wednesday: Wins for Healthcare as Novocure and Merck Soar; GameStop and Reddit Stumble

US equities are mostly higher on Wednesday at midday, after stocks fell for a third straight session on Tuesday. Outperformers include hospitals, apparel manufacturers, homebuilders, credit cards, investment banks, and commodity chemicals, while underperformers include cruise lines, beverages, semi cap equipment, oil majors, E&Ps, and marine shipping. Treasuries are firmer, the Dollar index is flat, Gold… [Read More]
March 27, 2024

Enveric Biosciences Marks Significant Progress in Corporate Update

Enveric Biosciences (Nasdaq: ENVB) has provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023. “The fourth quarter of 2023 and early 2024 was a significant period for Enveric, highlighted by the selection of EB-003 as our lead development candidate. We believe EB-003 is… [Read More]
March 27, 2024

Stock Market Volatility Intensifies as Quarter End Approaches: A Comprehensive Overview

Goldman Sachs predicts pension funds to divest $32 billion in stocks Stocks surge nearly 10% this quarter, outperforming bonds Amid anticipation of portfolio rebalancing following a significant market rally, stock markets experienced heightened volatility. The S&P 500 saw its earlier gains cut by half, while the Nasdaq 100 reversed its positive performance. Nvidia Corp. ($NVDA)… [Read More]
March 27, 2024

Viking Shares Surge on Positive Results for Obesity Treatment

Shares in Viking Therapeutics (Nasdaq: VKTX) surged on Tuesday after the company announced positive results from its Phase 1 clinical trial evaluating its oral tablet formulation of VK2735, which is in development for the potential treatment of metabolic disorders, including obesity. The company’s share price settled up 16.82% on Tuesday, gaining an additional 2.75% in… [Read More]